329 related articles for article (PubMed ID: 30799656)
1. Low-density lipoprotein decorated silica nanoparticles co-delivering sorafenib and doxorubicin for effective treatment of hepatocellular carcinoma.
Ye J; Zhang R; Chai W; Du X
Drug Deliv; 2018 Nov; 25(1):2007-2014. PubMed ID: 30799656
[TBL] [Abstract][Full Text] [Related]
2. Low-density lipoprotein-decorated and Adriamycin-loaded silica nanoparticles for tumor-targeted chemotherapy of colorectal cancer.
Shi G; Li J; Yan X; Jin K; Li W; Liu X; Zhao J; Shang W; Zhang R
Adv Clin Exp Med; 2019 Apr; 28(4):479-487. PubMed ID: 30070081
[TBL] [Abstract][Full Text] [Related]
3. Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib.
Duan W; Liu Y
Drug Des Devel Ther; 2018; 12():2149-2161. PubMed ID: 30034219
[TBL] [Abstract][Full Text] [Related]
4. iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy.
Zhang J; Hu J; Chan HF; Skibba M; Liang G; Chen M
Nanomedicine; 2016 Jul; 12(5):1303-11. PubMed ID: 26964482
[TBL] [Abstract][Full Text] [Related]
5. Negative-charge-functionalized mesoporous silica nanoparticles as drug vehicles targeting hepatocellular carcinoma.
Xie M; Xu Y; Shen H; Shen S; Ge Y; Xie J
Int J Pharm; 2014 Oct; 474(1-2):223-31. PubMed ID: 25149125
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab modified silica nanoparticles loaded with doxorubicin for targeted and synergic therapy of breast cancer.
Meng LX; Ren Q; Meng Q; Zheng YX; He ML; Sun SY; Ding ZJ; Li BC; Wang HY
Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S556-S563. PubMed ID: 30146920
[TBL] [Abstract][Full Text] [Related]
7. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.
Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L
Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690
[TBL] [Abstract][Full Text] [Related]
8. A dual-targeting reconstituted high density lipoprotein leveraging the synergy of sorafenib and antimiRNA21 for enhanced hepatocellular carcinoma therapy.
Li M; Su Y; Zhang F; Chen K; Xu X; Xu L; Zhou J; Wang W
Acta Biomater; 2018 Jul; 75():413-426. PubMed ID: 29859368
[TBL] [Abstract][Full Text] [Related]
9. Low-density lipoprotein-coupled N-succinyl chitosan nanoparticles co-delivering siRNA and doxorubicin for hepatocyte-targeted therapy.
Zhu QL; Zhou Y; Guan M; Zhou XF; Yang SD; Liu Y; Chen WL; Zhang CG; Yuan ZQ; Liu C; Zhu AJ; Zhang XN
Biomaterials; 2014 Jul; 35(22):5965-76. PubMed ID: 24768047
[TBL] [Abstract][Full Text] [Related]
10. Functional Doxorubicin-Loaded Omega-3 Unsaturated Fatty Acids Nanoparticles in Reversing Hepatocellular Carcinoma Multidrug Resistance.
Wang C; Wei X; Shao G
Med Sci Monit; 2021 Feb; 27():e927727. PubMed ID: 33524008
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
12. Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma.
Xue H; Yu Z; Liu Y; Yuan W; Yang T; You J; He X; Lee RJ; Li L; Xu C
Int J Nanomedicine; 2017; 12():5271-5287. PubMed ID: 28769563
[TBL] [Abstract][Full Text] [Related]
13. Co-delivery of plantamajoside and sorafenib by a multi-functional nanoparticle to combat the drug resistance of hepatocellular carcinoma through reprograming the tumor hypoxic microenvironment.
Zan Y; Dai Z; Liang L; Deng Y; Dong L
Drug Deliv; 2019 Dec; 26(1):1080-1091. PubMed ID: 31735093
[TBL] [Abstract][Full Text] [Related]
14. Low density lipoprotein modified silica nanoparticles loaded with docetaxel and thalidomide for effective chemotherapy of liver cancer.
Ao M; Xiao X; Ao Y
Braz J Med Biol Res; 2018 Jan; 51(3):1-10. PubMed ID: 29513882
[TBL] [Abstract][Full Text] [Related]
15. Low-density lipoprotein decorated and indocyanine green loaded silica nanoparticles for tumor-targeted photothermal therapy of breast cancer.
Pan H; Sun Y; Cao D; Wang L
Pharm Dev Technol; 2020 Mar; 25(3):308-315. PubMed ID: 31820663
[TBL] [Abstract][Full Text] [Related]
16. Low density lipoprotein receptor (LDLR)-targeted lipid nanoparticles for the delivery of sorafenib and Dihydroartemisinin in liver cancers.
Wang Z; Duan X; Lv Y; Zhao Y
Life Sci; 2019 Dec; 239():117013. PubMed ID: 31678287
[TBL] [Abstract][Full Text] [Related]
17. Combined treatment of sorafenib and doxorubicin-loaded microbubble-albumin nanoparticle complex for hepatocellular carcinoma: A feasibility study.
Lee S; Kim JH; Moon H; Lee HJ; Han JK
PLoS One; 2020; 15(12):e0243815. PubMed ID: 33306731
[TBL] [Abstract][Full Text] [Related]
18. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
[TBL] [Abstract][Full Text] [Related]
19. Enhancing Anti-Tumor Activity of Sorafenib Mesoporous Silica Nanomatrix in Metastatic Breast Tumor and Hepatocellular Carcinoma via the Co-Administration with Flufenamic Acid.
Li ZY; Yin YF; Guo Y; Li H; Xu MQ; Liu M; Wang JR; Feng ZH; Duan XC; Zhang S; Zhang SQ; Wang GX; Liao A; Wang SM; Zhang X
Int J Nanomedicine; 2020; 15():1809-1821. PubMed ID: 32214813
[TBL] [Abstract][Full Text] [Related]
20. Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles.
Zhao P; Li M; Wang Y; Chen Y; He C; Zhang X; Yang T; Lu Y; You J; Lee RJ; Xiang G
Acta Biomater; 2018 May; 72():248-255. PubMed ID: 29555460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]